KADVAX TECHNOLOGIES, INC.

Biotech · Private

KO-MA, a therapeutic vaccine conjugate linking methamphetamine to tetanus toxoid carrier protein with adjuvant system, designed to induce anti-methamphetamine antibodies for addiction treatment

Grants
$306K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Methamphetamine vaccine for Humans$305,976
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3227CELLGORTHMICS, INC——
3228ROCKLAND IMMUNOCHEMICALS, INC.——
3229GATACA, LLC——
3230KADVAX TECHNOLOGIES, INC.——
3231SONOVAL LLC——
3232ROSEBUD BIOSCIENCES INC.——
3233Therapeutic Vision, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.